Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02709889
Title Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Stemcentrx
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.